Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

• Published in: Blood Vol. 134; no. 18; pp. 1498 - 1509
• Main Authors: Yacoub, Abdulraheem, Mascarenhas, John, Kosiorek, Heidi, Prchal, Josef T., Berenzon, Dmitry, Baer, Maria R., Ritchie, Ellen, Silver, Richard T., Kessler, Craig, Winton, Elliott, Finazzi, Maria Chiara, Rambaldi, Alessandro, Vannucchi, Alessandro M., Leibowitz, David, Rondelli, Damiano, Arcasoy, Murat O., Catchatourian, Rosalind, Vadakara, Joseph, Rosti, Vittorio, Hexner, Elizabeth, Kremyanskaya, Marina, Sandy, Lonette, Tripodi, Joseph, Najfeld, Vesna, Farnoud, Noushin, Papaemmanuil, Elli, Salama, Mohamed, Singer-Weinberg, Rona, Rampal, Raajit, Goldberg, Judith D., Barbui, Tiziano, Mesa, Ruben, Dueck, Amylou C., Hoffman, Ronald
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 31.10.2019; American Society of Hematology
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Clinical Trials and Observations; Drug Resistance, Neoplasm - drug effects; Female; Humans; Hydroxyurea; Interferon-alpha - therapeutic use; Male; Middle Aged; Polycythemia Vera - drug therapy; Polyethylene Glycols - therapeutic use; Recombinant Proteins - therapeutic use; Thrombocythemia, Essential - drug therapy; Treatment Outcome

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients prev...